First Financial Corp IN cut its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 7.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,017 shares of the conglomerate’s stock after selling 76 shares during the period. First Financial Corp IN’s holdings in Danaher were worth $208,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Heck Capital Advisors LLC acquired a new stake in Danaher during the fourth quarter valued at $27,000. Golden State Wealth Management LLC acquired a new stake in Danaher in the fourth quarter valued at approximately $31,000. Hurley Capital LLC bought a new stake in Danaher in the fourth quarter worth approximately $34,000. Pineridge Advisors LLC increased its stake in shares of Danaher by 63.3% during the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after purchasing an additional 57 shares during the last quarter. Finally, Rialto Wealth Management LLC bought a new position in shares of Danaher during the 4th quarter valued at $34,000. Institutional investors and hedge funds own 79.05% of the company’s stock.
Insider Transactions at Danaher
In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the company’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares of the company’s stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
View Our Latest Analysis on DHR
Danaher Stock Down 0.5%
DHR opened at $189.04 on Tuesday. Danaher Co. has a twelve month low of $171.00 and a twelve month high of $281.70. The firm has a market cap of $135.29 billion, a price-to-earnings ratio of 35.80, a PEG ratio of 2.66 and a beta of 0.80. The firm’s 50-day simple moving average is $192.30 and its 200-day simple moving average is $213.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Equities research analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.
Danaher Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.68%. Danaher’s payout ratio is 24.85%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
- Five stocks we like better than Danaher
- How to Invest in the FAANG Stocks
- Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade
- How to Invest in Small Cap Stocks
- Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead
- What Does a Stock Split Mean?
- Top 3 ETFs Defense Hawks Are Buying
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.